Product News

Share this article:
GlaxoSmithKline says the US launch of HPV vaccine Cervarix will feature a slightly lower price than that of Merck's vaccine Gardasil, the Financial Times reports. GSK's new entrant will carry a wholesale cost of $386 for a three-course dose, compared with $399 for rival Gardasil, making the GSK vaccine more attractive for payers. The price strategy already has helped GSK win a vaccine contract in the UK.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.